Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2017 1
2019 2
2020 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.
Ochenduszko S, García Sanchez J, Fita MJJ, González-Barrallo I, Herrero Colomina J, Mujika K, Beveridge RD, Martínez SR, Lafuente BS, Tomas AC, Jaime AB, Cerezuela Fuentes P, Fra PL, Peeters AG, Meana García JA, García MAA, Altozano JP, Cancela M, Puchades AM, Roca FF, Maiques IM. Ochenduszko S, et al. Among authors: mujika k. Pigment Cell Melanoma Res. 2023 Sep;36(5):388-398. doi: 10.1111/pcmr.13093. Epub 2023 May 27. Pigment Cell Melanoma Res. 2023. PMID: 37243929
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D, Fernández-García P, Lladó V, McNicholl AG, Rosselló CA, Taylor RJ, Azaro A, Rodón J, Sludden J, Veal GJ, Plummer R, Urruticoechea A, Lahuerta A, Mujika K, Escribá PV. Lopez J, et al. Among authors: mujika k. Br J Cancer. 2023 Sep;129(5):811-818. doi: 10.1038/s41416-023-02356-1. Epub 2023 Jul 24. Br J Cancer. 2023. PMID: 37488446 Free PMC article. Clinical Trial.
The Circulating Transcriptome as a Source of Biomarkers for Melanoma.
Solé C, Tramonti D, Schramm M, Goicoechea I, Armesto M, Hernandez LI, Manterola L, Fernandez-Mercado M, Mujika K, Tuneu A, Jaka A, Tellaetxe M, Friedländer MR, Estivill X, Piazza P, Ortiz-Romero PL, Middleton MR, Lawrie CH. Solé C, et al. Among authors: mujika k. Cancers (Basel). 2019 Jan 10;11(1):70. doi: 10.3390/cancers11010070. Cancers (Basel). 2019. PMID: 30634628 Free PMC article.
BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.
Sevilla A, Morales MC, Ezkurra PA, Rasero J, Velasco V, Cancho-Galan G, Sánchez-Diez A, Mujika K, Penas C, Smith I, Asumendi A, Cortés JM, Boyano MD, Alonso S. Sevilla A, et al. Among authors: mujika k. PLoS One. 2020 Mar 13;15(3):e0230136. doi: 10.1371/journal.pone.0230136. eCollection 2020. PLoS One. 2020. PMID: 32168325 Free PMC article.
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
González-Barrallo I, Castellón Rubio VE, Medina J, España S, Mujika K, Majem M, Aguado C, Cabrera Suárez MÁ, Palacio I, Osterloh L, Martínez-Fernández A, García-Castaño A. González-Barrallo I, et al. Among authors: mujika k. Melanoma Res. 2022 Oct 1;32(5):343-352. doi: 10.1097/CMR.0000000000000837. Epub 2022 Jun 27. Melanoma Res. 2022. PMID: 35762583
Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.
Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS. Mohr P, et al. Among authors: mujika k. Melanoma Manag. 2019 Oct 4;6(4):MMT33. doi: 10.2217/mmt-2019-0015. Melanoma Manag. 2019. PMID: 31871622 Free PMC article.
Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study.
Mancuso F, Lage S, Rasero J, Díaz-Ramón JL, Apraiz A, Pérez-Yarza G, Ezkurra PA, Penas C, Sánchez-Diez A, García-Vazquez MD, Gardeazabal J, Izu R, Mujika K, Cortés J, Asumendi A, Boyano MD. Mancuso F, et al. Among authors: mujika k. Mol Oncol. 2020 Aug;14(8):1705-1718. doi: 10.1002/1878-0261.12732. Epub 2020 Jun 24. Mol Oncol. 2020. PMID: 32485045 Free PMC article.
Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.
Martín Algarra S, Soriano V, Fernández-Morales L, Berciano-Guerrero MÁ, Mujika K, Manzano JL, Puértolas Hernández T, Soria A, Rodríguez-Abreu D, Espinosa Arranz E, Medina Martínez J, Márquez-Rodas I, Rubió-Casadevall J, Ortega ME, Jurado García JM, Lecumberri Biurrun MJ, Palacio I, Rodríguez de la Borbolla Artacho M, Altozano JP, Castellón Rubio VE, García A, Luna P, Ballesteros A, Fernández O, López Martín JA, Berrocal A, Arance A. Martín Algarra S, et al. Among authors: mujika k. Medicine (Baltimore). 2017 Dec;96(52):e9523. doi: 10.1097/MD.0000000000009523. Medicine (Baltimore). 2017. PMID: 29384960 Free PMC article.